The partnership between clinical leaders at Harvard and manufacturing experts at Landmark Bio aims to bridge the gap between laboratory breakthroughs and clinical-grade therapies. For infants born with complex congenital heart defects, the current medical standard often involves a harrowing series
Manufacturing failures can occur if patients receive lymphodepleting agents like bendamustine too close to the collection of their therapeutic T cells. This biological reality creates a high-stakes environment for oncologists managing relapsed/refractory multiple myeloma, where the timing of every
Regulatory hurdles and the complexity of characterizing nanoparticle behavior in humans have slowed the progress of bone-targeted nanomedicines. Despite these significant challenges, osteosarcoma remains a primary concern in pediatric oncology due to its high rate of metastasis and the persistent
The persistent challenge of treating advanced HPV16-positive malignancies has driven medical science toward a more personalized approach that prioritizes early detection of treatment efficacy through minimally invasive methods. In the current landscape of oncology, researchers are increasingly
The silent progression of liver-induced cognitive decline has historically lacked a precise neuroimaging signature that accounts for both physiological structure and active neuronal firing. The application of regional homogeneity and amplitude of low-frequency fluctuation ratios has uncovered
Triple-negative breast cancer remains a significant therapeutic challenge due to its aggressive nature and the absence of common hormonal receptors. Because patients lack estrogen, progesterone, and HER2 receptors, standard endocrine therapies and HER2-targeted treatments are ineffective, leaving
